Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PRVL

Prevail Therapeutics (PRVL) Stock Price, News & Analysis

Prevail Therapeutics logo

About Prevail Therapeutics Stock (NASDAQ:PRVL)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$23.00
$23.00
50-Day Range
$22.91
$23.20
52-Week Range
$9.02
$23.35
Volume
N/A
Average Volume
955,800 shs
Market Capitalization
$787.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Remove Ads
Receive PRVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prevail Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRVL Stock News Headlines

Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

PRVL Stock Analysis - Frequently Asked Questions

Prevail Therapeutics Inc. (NASDAQ:PRVL) announced its earnings results on Friday, November, 13th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.09.

Prevail Therapeutics (PRVL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prevail Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Alector (ALEC), Advanced Micro Devices (AMD), Atreca (BCEL) and Homology Medicines (FIXX).

Company Calendar

Last Earnings
11/13/2020
Today
4/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVL
CIK
N/A
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-63,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.85 per share
Price / Book
4.74

Miscellaneous

Free Float
N/A
Market Cap
$787.66 million
Optionable
Not Optionable
Beta
1.59
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:PRVL) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners